Research Use Only / Third-Party Analytical Testing / Per-Batch Documentation / Materials Shipped from the USA
Search Account 0 Cart
BPC-157 Capsules research material
Capsules · Research materialHelio®
Helio / Materials / Recovery
Recovery Research

BPC-157 Capsules

This product presents BPC-157 in an oral capsule format for laboratory research workflows that favor solid-dose handling. BPC-157 is a synthetic pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with molecular formula C62H98N16O22, a molecular weight of approximately 1419.5 g/mol, CAS 137525-51-0 and PubChem CID 9941957. The peptide is derived from a protein sequence originally isolated from human gastric juice and is recognized in the literature for relative stability in aqueous and acidic conditions.

The oral (gastric-juice-origin) route is of particular interest in gastrointestinal research, where the compound has been examined in mucosal-injury and connective-tissue models with proposed angiogenic and nitric-oxide-mediated mechanisms. Helio offers BPC-157 capsules in 30-count and 60-count configurations. This material is Research Use Only and is not intended for human or veterinary consumption.

Identification
  • MaterialBPC-157 Capsules
  • Research AreaRecovery
  • PresentationCapsules
  • Available Sizes30ct · 60ct
  • CAS Number137525-51-0
  • Molecular FormulaC62H98N16O22
  • Molecular Weight1419.5 g/mol
  • TypeSynthetic pentadecapeptide
  • Receptor / TargetNo single defined receptor; investigated via VEGFR2 and nitric oxide (NO) / eNOS-Akt signaling in preclinical models
  • PubChem CID9941957 →
Amino Acid Sequence

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)

Analytical Data
  • Purity (HPLC)≥99%
  • Identity (MS)Confirmed to specification
  • TestingAccredited (ISO 17025) third-party laboratory
  • DocumentationPer-batch COA →
From$49.00 – $99.99

Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.

Key Characteristics
Molecular FormulaC62H98N16O22
Molecular Weight~1419.5 g/mol
CAS Number137525-51-0
PubChem CID9941957
StructureLinear synthetic pentadecapeptide (15 amino acids)
Receptor / TargetNo defined receptor; studied via VEGFR2 and NO/eNOS-Akt angiogenic signaling
FormOral capsule
SolubilityPeptide soluble in water and acidic aqueous media
StorageStore capsules cool, dry and away from light; refrigerate for extended storage
StabilityReported stability in aqueous and gastric-acid environments; protect from light, heat and humidity
Research Context
Gastrointestinal mucosaStudied in gastric ulcer, colitis and fistula models consistent with its gastric-juice origin and oral relevance.
AngiogenesisInvestigated for VEGF up-regulation and blood-vessel formation via the VEGFR2 pathway.
Tendon & ligament repairExamined in tendon and ligament injury models for fibroblast and collagen endpoints.
Nitric oxide signalingExplored for interaction with the NO / eNOS-Akt cytoprotective system.
Systemic cytoprotectionAssessed across multiple organ-injury models as a broad protective agent.
Research Findings

Because BPC-157 originates from a gastric-juice protein and shows reported stability in acidic media, oral-route studies have featured prominently in the preclinical record, particularly for gastrointestinal mucosal repair and systemic cytoprotection. Investigators including Sikiric and Seiwerth report angiogenic and nitric-oxide-linked effects across a range of rodent models.

These are experimental animal and in-vitro findings; human efficacy and pharmacokinetics of any oral format have not been established. The capsule presentation is provided solely as a research material.

History

BPC-157 was derived in the 1990s from Body Protection Compound, a peptide fraction of human gastric juice, and has been characterized in an extensive experimental literature (also known as PL 14736). It remains an unapproved investigational compound intended only for laboratory research.

References
  1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-1632.
  2. Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and blood vessels. Current Pharmaceutical Design. 2014;20(7):1121-1125.
  3. Sikiric P, Seiwerth S, Brcic L, et al. Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2010;16(10):1224-1234.
  4. Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats. Journal of Physiology and Pharmacology. 2008;59(Suppl 7):45-58.

View compound profile on NIH PubChem →

Cited literature refers to laboratory and preclinical research. BPC-157 Capsules is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.

Why researchers choose Helio
99%+ PurityHPLC-verified every batch
Accredited TestingIndependent ISO 17025 laboratory
Per-Batch COADocumentation tied to your lot
Made in the USADiscreet, protected shipping
Related

More in Recovery

View area →